Name | SBI-0206965 |
---|---|
Synonyms |
2-({5-Bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl}oxy)-N-methylbenzamide
Benzamide, 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]oxy]-N-methyl- |
Description | SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50 of 108 nM for ULK1 kinase activity and 711 nM for the highly related kinase ULK2 .IC50 value: 108nM/711 nMTarget: ULK1/ ULK2in vitro: SBI-0206965 has very high selectivity, only inhibits 10 out of 456 kinases >95% when tested at 10 μM. SBI-0206965 suppressed ULK1-mediated phosphorylation events in cells, regulating autophagy and cell survival It can suppress autophagy induced by mTOR inhibition, prevent ULK1-dependent cell survival following nutrient deprivation. It greatly synergized with mechanistic target of rapamycin (mTOR) inhibitors to kill tumor cells, providing a strong rationale for their combined use in the clinic. |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C21H21BrN4O5 |
Molecular Weight | 489.319 |
Exact Mass | 488.069519 |
LogP | 3.26 |
Index of Refraction | 1.619 |
Storage condition | -20℃ |